Voucher Scheme

Phenomics Australia offers a voucher scheme to facilitate and encourage access to one or more Phenomics Australia facilities. This scheme is intended to further reduce the cost of access to a specific capability.

Pipeline Accelerator - Voucher Scheme

Access the Pipeline

Through the National Collaborative Research Infrastructure Strategy (NCRIS) program, Phenomics Australia, Therapeutic Innovation Australia (TIA) and ANSTO seamlessly support a network of national research infrastructure to address the medical products challenge in the 2021 National Research Infrastructure (NRI) Roadmap. We collectively offer academic researchers and SMEs access to a diverse range of Australian translational medical research capabilities, from the molecular basis of health and disease through to clinical trials.

To encourage access to these capabilities, TIA has developed the Pipeline Accelerator, a voucher-style scheme that supports the cost of access to a broad range of advanced capabilities. In this Pipeline Accelerator round, Phenomics Australia is partnering with TIA and ANSTO’s National Deuteration Facility (NDF) to expand the list of translation expertise necessary for the discovery and translation of medical research.

This scheme aims to support therapeutic development projects by providing up to $50,000 with at least 50% matching co-investment to be provided by the applicant.

Refer to the guidelines for information on eligibility, funding levels, co-investment expectations, as well as the application and funding process. All applicants are required to complete and submit the applications online. The link to the application form can be found in the guideline document. We strongly advise you to develop your application on the provided template as the online form cannot be saved and retrieved at a later date.

Applications close on 26th April 2024, 5pm (AEST).

Voucher scheme documents

Please click on buttons below to download the appropriate documents for the current round.

Voucher Scheme Webinars

If you have any questions regarding our voucher schemes, you are invited to check our virtual information session which was held on the 14th of March 2023, 12pm AEST

More information

For further information about the voucher scheme, please contact:

Pipeline Accelerator FAQs

Search for an answer here

Pipeline Accelerator Outcomes

All awarded Pipeline Accelerator projects will be listed here.

Round

Lead applicant

Affiliation

Project title

Phenomics Australia node ( Capability provider)

23_24_Round 2

Dr Allara Zyberberg

Murdoch Children’s Research Institute

Developing reporter lines to enhance human kidney micro-organoids

Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility

23_24_Round 2

Dr Andrew Bejoy Das

Murdoch Children’s Research Institute

High-throughput identification of targets that improve kidney organoid generation protocols

Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility and Victorian Centre for Functional Genomics

23_24_Round 2

Dr Chun Yuen Chow

The University of Queensland

A novel therapeutic intervention for genetic epilepsies using spider-venom peptides

Genome Engineering and Disease Modelling Service (UQ - AIBN).

23_24_Round 2

Dr Chengxue  Qin

Monash University

Development of Humanised Mice to Improve the Translatability for Cardiopulmonary Disease

Monash Genome Modification Platform

23_24_Round 2

Prof. Deborah Marsh 

University of Technology Sydney

FDA-approved therapeutic compound library screen to discover new drugs to treat ARID1A mutant ovarian cancer

ANU Centre for Therapeutic Discovery

23_24_Round 2

Dr Dilys Leung

Monash University

Identification of personalised treatment strategies for breast cancer through high-throughput screening

Victorian Centre for Functional Genomics and Monash Organoid Program

23_24_Round 2

Dr Laura Cook

University of Melbourne

A high throughput human organoid model to measure effects of co-cultured immune cells

Victorian Centre for Functional Genomics

23_24_Round 2

Dr Louise Robertson

The University of Adelaide

Next-generation CRISPR therapeutics for autosomal dominant retinitis pigmentosa

Phenomics Australia node: South Australia Genome Editing Facility

Therapeutics Innovation Australia node: Vector and Genome Engineering Facility

23_24_Round 2

Dr Natasha Kelly Tuano

Murdoch Children’s Research Institute

Deciphering the role of the kinome in skeletal muscle and their potential use as a therapeutic target in disease

Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility and Monash Functional Genomics Platform

23_24_Round 2

Dr Xaria X Li

The University of Queensland

Developing new tools to enable the translation of complement therapeutics for human disease

Monash Genome Modification Platform

23_24_Round 2

Dr Yuanzhao Cao

The University of Queensland

A chloride ion channel as a novel therapeutic target for ischaemic heart disease

Monash Genome Modification Platform

23_24_Round 1

Dr Suad Mohamed Abdirahman

Peter MacCallum Cancer Centre

High throughput screening to identify new therapeutic strategies for mucinous ovarian cancer patients

Victorian Centre for Functional Genomics

23_24_Round 1

Dr Nicole J. Van Bergen

Murdoch Children's Research Institute

Development of iPSC models for ASO screening for TRAPPC4 neurodevelopmental disorder

Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility

23_24_Round 1

Ms Rikki Brown

Harry Perkins Institute

Generation of Oral Carcinoma Patient-Derived Organoids for Personalised Cancer Research

Perkins Cancer Biobank

23_24_Round 1

Dr Rebekah Engel

Monash University and Cabrini Health

Personalised treatment strategies for patients with early-onset metastatic colorectal cancer

Victorian Centre for Functional Genomics and Monash Functional Genomics Platform

23_24_Round 1

Dr Iva Nikolic

oNKo-Innate Pty Ltd

Methodology development for high-throughput compound screening of primary human immune cell cytotoxicity in 3D

Victorian Centre for Functional Genomics

23_24_Round 1

Dr Remy Robert

Monash University

Development of human GPCR knock-in mice for assessment of therapeutic antibodies

Melbourne Advanced Genome Editing Centre

23_24_Round 1

Dr Naisana Seyedasli

University of Sydney & Centre for Cancer Research

Establishing a targeted treatment strategy using epigenetic reprogramming against adverse EMT-induced tumour plasticity in head and neck (oral) squamous cell carcinoma

Monash Genome Modification Platform

23_24_Round 1

Dr Holly Voges

Murdoch Children's Research Institute

Developing a human induced pluripotent stem cell reporter line for heart valve disease modelling

Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility

23_24_Round 1

Dr Kevin Watt

Murdoch Children's Research Institute

Generation of mouse models of inherited heart failure to test the efficacy of novel stem cell based therapies

Melbourne Advanced Genome Editing Centre

22_23_Round 2

Prof James Hudson

QIMR Berghofer

Development of an epicardial lineage tracing human pluripotent stem cell line to identify new cardiac therapeutics

Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility

22_23_Round 2

Dr Graham A. Mackay

The University of Melbourne

MRGPRX2-dependent activation of mast cells: insight to novel therapeutic innovation

Victorian Centre for Functional Genomics

22_23_Round 2

Dr Brett McKinnon

The University of Queensland

High throughput screening of micro-organoids for assessing heterogeneity and precision medicine potential in endometriosis

Victorian Centre for Functional Genomics

22_23_Round 2

Dr Zhian Chen

The University of Queensland

The role of ferroptosis and oxidative stress in regulating immunity

Monash Genome Modification Platform

22_23_Round 2

Dr Svenja Pachernegg

Murdoch Children's Research Institute

Using iPSCs to determine the role of NR2F2 in ovarian development and 46,XX sex reversal

Induced Pluripotent Stem Cell Derivation & CRISPR Gene EditingFacility

22_23_Round 2

Dr Ada Koo

The University of Melbourne

Developing transcriptomic and morphological profiling of macrophages to mine the microbiome

Victorian Centre for Functional Genomics

22_23_Round 2

Dr Alexander Nicholas Combes

Monash University

New therapeutic strategies and targets to suppress acute kidney injury

Victorian Centre for Functional Genomics and Monash Functional Genomics Platform

22_23_Round 2

Dr Simon Preston

Anaxis Pharma Pty Ltd

Evaluating human organoids as model systems in drug development

Monash Organoid Program

22_23_Round 2

A/Prof Edwina McGlinn

Monash University

Tick tock, tick tock… Mechanisms pacing the Hox clock

Monash Functional Genomics Platform

“Phenomics Australia supports world-class infrastructures and the development of cutting-edge technologies, enabling research excellence in Australia. Within the In Vitro Genome Engineering and Disease Modelling node, the Monash Organoid Program helps Scientists around the Country generate novel in vitro organoid models, by producing key cell culture reagents, assisting with organoid establishment, performing a wide range of assays for phenotypic characterisation and training the future generation of research leaders. “ Dr Jardé said.

Therapeutic Innovation Australia (TIA) is a national consortium of translational research infrastructure with a focus on the development of new therapeutic products such as biologics and vaccines, cell and gene therapies as well as small molecule pharmaceuticals. More information here.